DGFT Fixes Export Quota For Covid Test Kits, Asks Exporters To Apply Online From Aug 10-17

Mumbai : The Directorate General Of Foreign Trade (DGFT) has fixed a quota for export of diagnostic kits and their components/laboratory reagents for three months starting July, 2021 and invited online applications from exporters for the same from August 10-17.

As per the DGFT notification on August 9, 2021, exporters can make outbound shipments of 2504 lakh RT-PCR kits from July-September 2021.

Similarly, exporters have been allowed to export 886 lakh RNA extraction kits or its component elements (silicone columns, poly adenylic acid or carrier RNA, proteinase K, magnetic stands, beads) for the three months.

The directorate has allowed export of 1,700 lakh VTM kits or its component elements (15 ml falcon tube or cryovials, sterile synthetic fibre swabs (nylon, polyster, rayon or Dacron) for the same period.

Exporters are requested to apply online for export of diagnostic kits (VTM/RNA extraction kits/RT-PCR kits) or their components/laboratory reagents for the above quantities from August 10-17, 2021, stated the DGFT notification.

Exporters have been asked to apply for an export license by filing applications online through DGFT’s ECOM system for export authorizations (non-SCOMET restricted items).

It is noteworthy that validity of the export license will be for six months only.

The eligibility criteria which will be applicable for consideration of applications include documentary proof of manufacturing “VTM/RNA extraction kits/RT-PCR kits, copy of purchase order /invoice and copy of IEC.

The documents to be submitted include undertaking duly signed by the authorized signatory in the company letter head to be submitted by the manufacturer certifying that as on date, all domestic commitments/orders have been fulfilled. All the documents must be duly self-attested by the authorized person of the firm.

Earlier, the directorate had fixed a quota for export of diagnostic kits and their components/laboratory reagents for the period from December, 2020 to February 2021 through trade notice dated January 19, 2021. The exporters were asked to apply online for export of these items from March 4-9, 2021.

In a bid to deal with Covid-19 pandemic, DGFT in a notification on June 10, 2020 has put restriction on export of 15ml falcon tube or cryovials, swabs sterile synthetic fibre swabs (nylon, polyester, rayon or Dacron), silicon columns, poly adenylic acid or carrier RNA, proteinase K, magnetic stand, beads, probes (specific for Covid-19 testing), primers (specific for Covid-19 testing), taq polymerase enzyme, reverse transcriptase enzyme, deoxy nucleotide triphosphates amid surge in coronavirus cases.

The export of all these products was allowed before the notification.

  • Related Posts

    • Pharma
    • June 19, 2025
    • 60 views
    Pharma stock jumps after receiving approval from UK’s MHRA to sell new pharma product

    This small-cap pharma stock, engaged in the research, manufacturing, and marketing of generic pharmaceutical formulations across global markets, rose over 2% in today’s trade after receiving approval for its product…

    • Pharma
    • June 19, 2025
    • 97 views
    HIV prevention drug hailed as a ‘breakthrough’ gets FDA approval

    A drug with the potential to drastically curb the HIV epidemic just cleared its first regulatory hurdle. On Wednesday, the Food and Drug Administration approved lenacapavir for the prevention of…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Pharma stock jumps after receiving approval from UK’s MHRA to sell new pharma product

    Pharma stock jumps after receiving approval from UK’s MHRA to sell new pharma product

    HIV prevention drug hailed as a ‘breakthrough’ gets FDA approval

    HIV prevention drug hailed as a ‘breakthrough’ gets FDA approval

    ED raids three pharma units in Baddi, Nalagarh

    ED raids three pharma units in Baddi, Nalagarh

    Glenmark Pharma: FDA concludes inspection at US facility, issues five observations

    Glenmark Pharma: FDA concludes inspection at US facility, issues five observations